Difference between revisions of "Axicabtagene ciloleucel (Yescarta)"
Jump to navigation
Jump to search
Line 13: | Line 13: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
− | *10/18/2017: Granted initial FDA approval for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including [[diffuse large B-cell lymphoma|diffuse large B-cell lymphoma (DLBCL) not otherwise specified]], [[Primary mediastinal B-cell lymphoma|primary mediastinal large B-cell lymphoma]], [[high-grade B-cell lymphoma]], and [[Transformed lymphoma|DLBCL arising from follicular lymphoma]]. NOT indicated for the treatment of patients with primary central nervous system lymphoma. | + | *10/18/2017: Granted initial FDA approval for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including [[diffuse large B-cell lymphoma|diffuse large B-cell lymphoma (DLBCL) not otherwise specified]], [[Primary mediastinal B-cell lymphoma|primary mediastinal large B-cell lymphoma]], [[high-grade B-cell lymphoma]], and [[Transformed lymphoma|DLBCL arising from follicular lymphoma]]. NOT indicated for the treatment of patients with primary central nervous system lymphoma. ''(Based on ZUMA-1)'' |
− | *3/5/2021: Granted accelerated approval for adult patients with relapsed or refractory [[Follicular lymphoma|follicular lymphoma (FL)]] after two or more lines of systemic therapy. | + | *3/5/2021: Granted accelerated approval for adult patients with relapsed or refractory [[Follicular lymphoma|follicular lymphoma (FL)]] after two or more lines of systemic therapy. ''(Based on ZUMA-5)'' |
==Also known as== | ==Also known as== |
Revision as of 00:47, 26 May 2021
Mechanism of action
From the NCI Drug Dictionary: A preparation of autologous peripheral blood T-lymphocytes (PBTL) that have been transduced with a gammaretroviral vector expressing a chimeric antigen receptor (CAR) consisting of an anti-CD19 single chain variable fragment (scFv) coupled to the costimulatory signaling domain CD28 and the zeta chain of the T-cell receptor (TCR)/CD3 complex (CD3 zeta), with potential immunostimulating and antineoplastic activities. Upon intravenous infusion and re-introduction of axicabtagene ciloleucel into the patient, these cells bind to and induce selective toxicity in CD19-expressing tumor cells.
Link to REMS
Diseases for which it is used
- Diffuse large B-cell lymphoma
- Follicular lymphoma
- High-grade B-cell lymphoma
- Primary mediastinal B-cell lymphoma
- Transformed lymphoma
Patient Drug Information
History of changes in FDA indication
- 10/18/2017: Granted initial FDA approval for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma. NOT indicated for the treatment of patients with primary central nervous system lymphoma. (Based on ZUMA-1)
- 3/5/2021: Granted accelerated approval for adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy. (Based on ZUMA-5)
Also known as
- Code name: KTE-C19
- Generic names: Axicel, Axi-cel
- Brand name: Yescarta